concizumab-mtci

concizumab-mtci (ALHEMO) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

ALHEMO is a marketed brand name for concizumab-mtci. Check FDA Drugs@FDA for the current US label holder and prescribing information.

concizumab-mtci has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.